1261238-08-7

Basic information

• Product Name: tert-butyl 5-(3,4-diamino-phenoxy)pentylcarbamate
• Synonyms: tert-butyl 5-(3,4-diamino-phenoxy)pentylcarbamate
• CAS NO: 1261238-08-7
• Molecular Weight: 309.409
• Mol File: 1261238-08-7.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: tert-butyl 5-(3,4-diamino-phenoxy)pentylcarbamate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 5-(3,4-diamino-phenoxy)pentylcarbamate(1261238-08-7)
• EPA Substance Registry System: tert-butyl 5-(3,4-diamino-phenoxy)pentylcarbamate(1261238-08-7)

Safety Data

• Hazardous Substances Data: 1261238-08-7(Hazardous Substances Data)

Upstream product

• 1261238-07-6 tert-butyl 5-(4-amino-3-nitrophenoxy)pentylcarbamate 
• 262278-05-7 tert-butyl (5-iodo-pentyl)-carbamate 
• 142342-55-0 diethyl {5-[(tert-butoxycarbonyl)amino]pentyl }-propanedioate 
• 75178-90-4 N-(tert-butyloxycarbonyl)-5-aminopentanol 
• 34619-03-9 tert-butyldicarbonate 
• 2508-29-4 5-hydroxypentylamine 

Relevant articles and documents

Synthesis of a DOTA (Gd3+)-conjugate of proton-pump inhibitor pantoprazole for gastric wall imaging studies

Magnetic resonance imaging (MRI) is used to evaluate gastrointestinal (GI) structure and functions in humans. Despite filling the viscus lumen with a contrast agent, visualization of the viscus wall is limited. To overcome this limitation, we de novo synthesized a conjugate that covalently combines a Gd-based MRI contrast agent, encaged with a chelating agent (DOTA), with pantoprazole, which is a widely used proton pump inhibitor that binds to proton pumps in the stomach and colon. The DOTA linkage was installed at a mechanism-based strategic location in the pantoprazole molecule to minimize a possible negative effect of the structural modification on the drug. It is anticipated that by defining the wall of the stomach and colon, this compound will facilitate functional MRI of the GI tract in humans.